Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours

Publisher： Karger

E-ISSN： 1662-6575|4|1|204-210

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.4, Iss.1, 2011-04, pp. : 204-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 326-332

Karger

Access to resources Recommend Favorite

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-03 ,pp. : 134-142

Karger

Access to resources Recommend Favorite

Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 157-161

Karger

Access to resources Recommend Favorite

Optimal Use of Targeted Agents for Advanced Gastrointestinal Stromal Tumours

By  

Oncology, Vol. 78, Iss. 2, 2010-04 ,pp. : 130-140

Karger

Access to resources Recommend Favorite

Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 324-327

Karger

Access to resources Recommend Favorite